Heltz Sabrina sold (to issuer) $34K of VMD

Heltz Sabrina sold (to issuer) 3,757 shares of VIEMED HEALTHCARE, INC. (VMD) at $8.94 on 2026-08-19.

Original reporting
SEC EDGAR · Heltz Sabrina
Published Aug 19, 2026, 8:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 19, 2026, 10:32 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$VMD
Neutral
high confidence
Mentioned
$VMD
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$VMDNeutralLow
01

Why it matters

The transaction is a routine insider sale with limited market effect.

02

Market read

Minor insider sale; unlikely to move the stock significantly.

03

What to watch

Potential upcoming corporate actions not disclosed.

Relevance 3/10Novelty 4/10Timing: today

Background

Form 4 filing reports insider transactions; required by SEC for directors.

Company-level read

Ticker impact

$VMDNeutralHigh confidence
Context

Director Heltz Sabrina sold 3,757 shares for $33,587.58, reducing her holdings to 82,520 shares.

Expected impact

Minimal downward pressure, likely negligible.

Evidence & confidence

Sale size is small relative to float and market cap; typical for directors.

Market effects

None

None

None

Counterpoint

Insider sale could be interpreted as lack of confidence, but size is trivial.

Key entities

  • Viemed Healthcare, Inc.

    Issuer of the shares sold.

  • Heltz Sabrina

    Insider reporting the sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$VMDMedAI 8/10

Viemed Healthcare Q3 Earnings Call Highlights

VieMed Healthcare (VMD) reported Q3 operating cash flow of $11.5M and free cash flow of $4M. The company expects Q4 improvements in collections and active ventilator patients. Full-year revenue guidance was raised to $316M-$320M, while adjusted EBITDA was narrowed to $64M-$66M. VieMed had $9.7M in cash and $5.3M in borrowings at Q3's end, with a $1M share buyback and $2M term-loan repayment in October.

$VMDMed

Viemed Healthcare Inc (VMD) (Q3 2026) Earnings Call Highlights: Record Revenue

Viemed Healthcare reported Q3 2026 record revenue of $80M. CEO Casey Boyd discussed state rollout timelines, expecting gradual growth. CFO Trey Fitzgerald addressed sequential growth gaps, seasonal trends, and financial KPIs, targeting EBITDA above 20%. Accounts receivable delays impacted cash flow but are expected to resolve in Q4. Boyd also updated on sales force training, M&A pipeline, and patient education progress.

$VMDMed

VIEMED HEALTHCARE ANNOUNCES THIRD QUARTER 2026 FINANCIAL RESULTS

VIEMED HEALTHCARE, INC. (VMD) filed an SEC Form 8-K — Results of Operations and Financial Condition. VIEMED HEALTHCARE ANNOUNCES THIRD QUARTER 2026 FINANCIAL RESULTS Lafayette, Louisiana (November 4, 2026) Viemed Healthcare, Inc. (the “Company” or “Viemed”) (NASDAQ:VMD), a national provider of technology-enabled, home-based healthcare solutions and chronic disease management, an

$VMDMedAI 8/10

Viemed Healthcare Targets Low-20% Growth as Home Ventilation Opportunity Expands

Viemed Healthcare (NASDAQ: VMD) anticipates low-20% revenue growth in 2026, with projected revenue of $317M and EBITDA of $66M. The company's ventilator business averages $1,050 monthly per rental, with an average patient length of 17 months. Viemed has expanded into sleep therapy, maternal health, and other areas, completing three acquisitions in the past three years. The company has no net debt and has repurchased nearly 700,000 shares. Management sees organic growth and strategic acquisitions